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ABSTRACT
Amphiphilic excipients, such as surfactants, have been shown to be inhibitors of the multidrug
resistance  (MDR) efflux pump transporter protein, P-glycoprotein (Pgp). In vitro studies using many
surfactants have demonstrated that those with an optimum hydrophilic-lipophilic balance (HLB)
exhibit greater efflux pump inhibition than those that are either very hydrophobic, or very
hydrophilic, although the correlation of HLB to Pgp inhibition activity remains weak. Using the data
from multiple in vitro studies, a model has been conceptualized that underscores the attributes of
both the HLB and the critical micellar concentration (CMC), occurring in tandem, and unable of
being varied independently, as key determinants toward prediction of surfactant Pgp inhibition
activity. The algorithm that formalizes this concept provides a ‘semi-rational’ method of choosing
surfactants for a specific type of cancer for maximum inhibition of MDR.
KEY WORDS: Surfactant, P-glycoprotein, multidrug resistance, prediction, HLB, CMC, excipient, chemo-
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INTRODUCTION
The development of resistance to a broad range
of structurally dissimilar anticancer agents is a
major cause for the failure of chemotherapy.
Chemotherapeutic agents are pumped out of
cancer cells by transport proteins resulting in
clinical multidrug resistance (MDR). P-
glycoprotein (or Pgp or ABCB1) is one of these
proteins. It belongs to a group of transporter
proteins that are known as efflux pumps and
whose genes are encoded by the ATP binding
Cassette (ABC) gene family. Its expression in
chemo resistant cancers has been shown to
correlate with poor chemotherapeutic response
and prognosis.
Many excipients, particularly those which
possess amphiphilic properties, such as bile
salts, phospholipids, surfactants, anionic gums
and solubilizing agents have been identified as
potent inhibitors of Pgp. Many of these agents
have been evaluated in vitro for their potential to
reverse the multidrug resistance caused by Pgp. 
A correlation has been shown to exist between
certain molecular characteristics of surfactants
such as the density of electron donor and
acceptor sites and their capability to function as
multidrug resistance (MDR1) substrates (1, 2).
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depletion (5) of cholesterol in the cell
membrane has shown to be associated with
modulation of efflux pump function. The
cholesterol associative or perturbative activity
of surfactants could therefore be considered an
important attribute for modulating drug efflux
activity. The hydrophilic-lipophilic balance
(HLB) and the critical micellar concentration of
surfactants has been correlated with the
magnitude of their MDR efflux pump
modulating activity (6), as has the presence (and
number) of specific functional groups on the
molecule, such as oxyethylene. The charge
shielding ability of ionic surfactants has been
speculated to be involved in bypassing the
MDR mechanism of drug resistant cells (7).
Molar refractivity (8) and hydrophobicity have
also been associated with the magnitude of
MDR inhibition.
DEVELOPMENT OF THE CONCEPT
Several reports in the literature suggest that
surfactants with intermediate lipophilic pro-
perties demonstrate optimum modulation of P-
glycoprotein drug efflux activity. Pluronics with
an intermediate length of the propylene oxide
block (from 30 to 60 units) and HLB < 20 were
the most effective at inhibiting Pgp efflux in
bovine brain microvessel endothelial cells (9).
Structure-activity relationship studies of
tocopheryl polyethylene glycol succinate
(TPGS) analogs, demonstrated that rhodamine
123 permeation rate through Caco-2 cell mono-
layers was strongly influenced by the polyethy-
lene glycol chain length, with an optimum
linear PEG molecular weight between 1000 and
1500 Da (10). Surfactants with HLB values
between 10 and 17 were most the effective in
enhancing the intracellular accumulation of
Epirubicin in Caco-2 cells (11). Within a ho-
mologous series of Triton surfactants, maxi-
mum disruption of mitochondrial membranes
occurred at HLB values between 12.5 and 13.5
(6). The critical micellar concentration (11)
(CMC), lipophilicity, steric properties and
hydrogen-bonding capacity of surfactants have
all been implicated as general requirements for
MDR reversal. (12) Each of them appears to be
a necessary, but not sufficient, determinant of
MDR reversal activity.



































Polyoxyethylated castor oil, [Cremophor EL] 1680 0.12-0.18 '12-14
Dioctyl sodium sulfosuccinate, [Aerosol OT] 444 0.64 10.5
Pluronic F68 8400 0.04 29
Pluronic P85 4600 0.07 16
Tween 80 1310 0.01-0.02 15
Sodium dodecyl sulfate, [SDS] 288.4 6.0-8.0 40
Sodium deoxycholate 414.6 2.0-6.0 24-26
Benzalkonium chloride 354 0.04
Cetyl trimethyl ammonium bromide, [CTAB] 364.5 0.92 10
Pluronic L81 2750 0.024 2
Pluronic L61 2000 0.1 3
Polyoxyethylene monostearate [Myrj 52] 2047 0.05 15-16.9
Span 80 428.6 4.3
Pluronic F127 12600 0.04 22
The two attributes of CMC and HLB can be
used as predictors for the lipophilicity (13),
hydrogen bonding capacity and, to a certain
extent, the steric properties, of surfactant mole-
cules (at least within a homologous series) (14).
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It is therefore not unreasonable to assume that
the effectiveness of a particular surfactant as an
MDR reversing agent must be an (inverse)
function of the difference of its CMC and HLB
from certain optimal (i.e. values that result in
the greatest MDR inhibition) values of CMC
and HLB. Furthermore, precisely because of
the demonstration of such optimal (MDR
reversing) values in the literature, the function
may be assumed to be parabolic in nature, with
transporter inhibiting activity decreasing as the
values of CMC and HLB deviate from their
‘optimum’ values. 
The function used to arrive at a numerical value
of the effectiveness of a surfactant as an MDR
reversing agent is:
f(HLB,CMC)=1/{SQRT{[(HLB-8.5) ]  x  12
[(CMC-0.045) ]}}2
where,  SQRT stands for the square root. 
The difference between the HLB and the opti-
mum HLB (and the CMC and the optimum
CMC) are squared in order to account for the
fact that the HLB or CMC of surfactants may
be lesser or greater than their corresponding
optimum values. The square root is introduced
to negate the ‘squared’ operation. In effect,
therefore, the effectiveness of a particular
surfactant as an MDR reversant is calculated to
be an inverse function of the difference of its
CMC and HLB from the optimum values of
CMC and HLB respectively, as elaborated
earlier.
optThese ‘optimum values ‘ of CMC,(C ) and
optHLB, (H ), of 0.045 mM and 8.5 respectively,
represent the geometric mean of the CMCs and
HLBs  of the poly(oxyethylene-poly(oxypropy-
lene) (Pluronic) class of surfactants used in the
study from reference 12 (Table 2). While there
is no a’priori justification for using these
particular values from this particular study, it
can be seen that the former spans three orders
of magnitude and the latter includes a wide
range of HLBs.  Another reason for using the
data from this study as a ‘predictor set’, is that
the Pluronics are recognized as relatively non-
toxic agents and some have progressed to the
clinic as MDR inhibitors (15). According to
Berthelot, and consistent with London’s theory
of dispersive forces, the attraction constant
between dissimilar substances is represented by
the geometric mean of their individual internal
attraction constants. Because micelle formation
is driven, in part by dispersive forces, the
geometric mean of the CMCs' is better
representative of the optimal CMC, where
maximum transporter inhibition might be
expected to occur. Likewise, the HLB of
non-ionic surfactants has been shown to
correlate with the oil-water partition coefficient
and the solubility parameter (16). The solubility
parameter term arises as a result of the
geometric mean assumption (see above) in the
Scatchard-Hildebrand equation (17). Therefore,
the geometric mean of the HLBs' of individual
surfactants is more likely to yield an 'optimum'
HLB at which PgP inhibition might be
maximum.
The HLB and CMC of the two surfactants
designated ‘Fictional’ in the last two rows of
Table 2 were obtained as follows: From the
polynomial regression equation in Figure 1, the
maxmaximum value of x (x )  was calculated by
maxapplying the function, f(x ) = -b/2a, where a
and b are coefficients of x  and x respectively in2
maxthe polynomial equation. This value of x  of
3.97 was substituted in the polynomial equation
to determine the maximum value of y (the same 
Figure 1 Correlation between the last two columns
in Table 2.
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as the numerical value of f(HLB, CMC), where
the inhibition of the Pgp transporter is
expected to be maximum). 
The paired values of CMC and HLB of 0.1,
9.12 and 0.04, 1.8 respectively, were determined
by iteration of Equation 1 using f(HLB, CMC)
= 29.85. Hence, a pluronic surfactant with a
CMC of 0.1 mM and an HLB of 9.12 (or one
with a CMC of 0.04 mM and an HLB of 1.8)
would be expected to maximally accumulate
R123 in bovine brain microvessel endothelial
cells. The attributes of the surfactants
designated ‘Fictional’ in the tables that follow
were obtained similarly.
It should be noted that the data in Tables 2
through 6 (shown in Figures 1-5) was obtained
from in vitro experiments. The relevance of the
CMC, when such formulations are administered
intravenously and diluted by blood, is discussed
later.
Table 2 The effect of various Pluronics to increase the
accumulation of R123 in bovine brain microvessel
endothelial cells as presented in reference 12.
Surfactant CM C, m M HLB f(HLB,CM C)
Enhancem ent
factor
F88 0.246 28 0.255 1.5500
F108 0.022 27 2.350 1.6000
F127 0.003 22 1.764 1.2000
L35 5.260 19 0.018 1.5000
P85 0.065 16 6.667 2.7000
L64 0.483 15 0.351 2.2000
L43 2.162 12 0.135 2.0000
P103 0.006 9 51.282 2.7000
L81 0.023 2 6.993 2.8000
L101 0.002 1 3.101 2.2500
L121 0.001 1 3.023 1.4500
Fictional 0.100 9.12 29.851 3.9700
Fictional 0.040 1.8 29.851 3.9700
Table 3 Uptake of doxorubicin in MDR cells expressed as
a percentage of its uptake in drug sensitive cells. Human
leukaemic cell line CCRF-CEM and its MDR derivative
R100 as presented in reference 9.






n- Octylglucoside 14.500 12.5 0.017 19.0000
Triton X-100 0.550 13.5 0.396 45.3000
Triton X-114 0.300 12.4 1.006 41.4000
CHAPS 6.000 15 0.026 16.7000
CHAPSO 8.000 15 0.019 16.4000
Lubrol 0.090 9.7 18.519 43.5000
Tween 20 0.080 16.7 3.484 38.3000
Crem ophor EL 0.150 13 2.116 47.3000
Tween 80 0.015 15 5.128 50.9000
Fictional 0.29 9.12 10.7 63.39
Fictional 0.059 1.8 10.7 63.39
Figure 3 Correlation between the last two columns in
Table 4.
Figure 2 Correlation between the last two columns in
Table 3.
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Table 4 The relative inhibitory potency to inhibit
Rhodamine 123 (R123) efflux (relative to verapamil) for
several surfactants in murine monocytic leukemia cells
overexpressing P-glycoprotein as presented in reference
10. The CMC of the surfactants listed was measured in
Hank’s balanced salt solution.
relSurfactant CM C, m M HLB f(HLB,CM C) IP
TPGS 0.33 17 0.413 1.1
Cremophor EL 0.179 13.5 1.493 0.74
Pluronic L81 0.0145 2 5.044 0.85
Pluronic L61 0.1 3 3.306 1
Tween 80 0.023 15 5.35 0.67
Sodium dodecyl sulfate 1.04 40 0.032 0.5
Pluronic F68 0.357 29 0.156 0.45
Fictional 1.68 9.12 2.95 0.989
Fictional 0.196 1.8 2.95 0.989
Table 5 Enhancement of intracellular accumulation of
epirubicin in Caco-2 cells in the presence of various
surfactants as compared to accumulation of epirubicin
alone as presented in reference 11. CMC of the surfactants
was measured in Dulbecco’s modified Eagle medium.
Surfactant CM C, m M HLB f(HLB,CM C)
Enhancem ent
factor
span80 nd 4.3 nd 1.4000
brij30 0.360 9.7 2.646 1.7000
Tween 80 0.240 15 0.789 1.9000
Tween 20 0.270 16.7 0.542 1.9000




4.100 40 0.008 1.5000
Fictional 1.15 9.12 1.46 2.06
Fictional 0.15 1.8 1.46 2.06
Table 6 Enhancement of rhodamine-123 by Caco-2 cells
using methoxypolyethylene glycol-block-polycaprolactone
diblock polymers as presented in reference 18. CMC of the
surfactants was measured in 1,6-diphenyl-1,3,5-hexatriene
using fluorescence spectroscopy.
Surfactant CM C, m M HLB f(HLB,CM C)
Enhancem ent
factor
MePEG(17)-b-PCL(2) 3.210 16.6 0.039 1.2500
MePEG(17)-b-PCL(5) 0.250 12.2 1.318 3.5000
MePEG(17)-b-PCL(10) 0.005 8.4 251.889 1.6700
MePEG(45)-b-PCL(4) 0.275 18.3 0.444 1.4200
Fictional 0.0575 9.12 126.21 118.82
Fictional 0.0462 1.8 126.21 118.82
The usual obvious caveats apply to the analysis
and conclusions arrived at in this paper. The
correlation between the HLB and CMC of
surfactants generally apply within a given class
of structurally similar surfactants. However, in
this report, the correlation has been extended
to structurally and ionically disparate surfactant
classes. Mechanisms (by which Pgp inhibition
may occur) that are unrelated to the amphiphilic
properties of the surfactants (as related to the
disruption or rearrangement of the phospho-
lipid bilayer cell membrane) have not been ta-
ken into consideration. Such mechanisms, which
may include enzyme or apoptotic modulation
(19), ATP depletion (20), glutathione extrusion
(21) or mitochondrial reactive oxygen species
Figure 4 Correlation between the last two columns in
Table 5.
Figure 5 Correlation between the last two columns in
Table 6.
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modulation (22) may superimpose upon, or in-
deed, even predominate, the cell membrane
modulatory effect or the Pgp substrate effect of
these amphiphilic surfactants. The optimum
HLB and CMC values for surfactants to
demonstrate maximum transporter inhibition
have been assumed to be the geometric mean
of the values of selected Pluronic surfactants
and these ‘predictor set’ values have been used
to predict (HLB and CMC) values that result in
maximum inhibition across a variety of
structurally diverse surfactants, in different cell
cultures, for different classes of chemo-
therapeutic drugs. Furthermore, the CMC of
surfactants used in these different studies have
been measured in aqueous media of different
compositions or, in one instance, in an organic
solvent (Table 6).
The correlation coefficients (> 0.5,  except for
the data from reference 10, considered to be
significant for experiments conducted in
biological media) for the curve could be const-
rued as a validation of the optimal HLB/CMC
and the parabolic function approach hypothesis
for the selection of surfactants. However, it
should be remembered that any periodic
function can be made a sum of a set of simple
oscillating (sine/cosine) functions (23). Hence
the relatively high “goodness of fit” for the data
may not be a true indicator of the validation of
the hypothesis presented in this paper.
Furthermore, the lack of experimental points at
or around the ‘maxima’ of the parabolas’ lends
more uncertainty to the validity of the
hypothesis. This is especially evident from
Table 6, where the algorithm predicts a Pgp
inhibitory effect that is two orders of magni-
tude greater at the ‘optimum value’ than that
observed with surfactants with HLB, CMC
value combinations f(HLB,CMC) removed
from the ‘optimum’.
In this paper, the relative magnitude of the
MDR pump inhibition in a particular study was
compared for similar concentrations of the
different surfactants, except for the data
analysis presented in Table 2 which was
obtained from reference 12. The concentra-
tions of individual surfactants where maximal
inhibition was observed (for that surfactant)
were not used for comparison of their relative
MDR inhibition efficiencies, except for Table 2
where only this data was reported in the study.
All the analysis is therefore performed (for a
particular study) at the same surfactant concent-
ration, except for the analysis in Table 2. 
An interesting observation that emerges from
this concept is that, for a surfactant with a
given HLB, its CMC must assume different
values for its transporter inhibition activity to
be maximum in different cell cultures (and/or
in combinations with different drugs). Such
surfactants can be designed by changing the
structural attributes of the molecule while
making no changes to the ratio of the
hydrophilic to hydrophobic regions. In the case
of Pluronics, for example, one could introduce
branching while keeping the ratio of ethylene
oxide (EO) to propylene oxide (PO) monomers
constant or by changing the number of EO or
PO monomers in selected “blocks” in the
polymer (while keeping the total number of EO
and PO monomers constant). This observation
may also explain, in part, why the literature
shows a weak correlation between HLB and
efflux pump inhibition. It may very well be that
the combined attributes of HLB and CMC
must be considered together for efflux pump
inhibition prediction, as has been shown in this
paper.





concentration , m Ma
CM C (m M ),
from  Table 1
Crem ophor EL (Taxol ) 2.23 (0.09 ) 0.12 – 0.18® b
Pluronic L61 (SP1049C ) 0.015 0.1®




 Assuming a blood volume of 7 liters and a body surface area of 1.8 ma 2
The number in brackets represents the concentration of surfactant perb
hour of infusion time.
Surfactants whose concentration is below their
CMC are expected to dissociate (from micellar
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structures) into unimers. The mechanism of
MDR inhibition by surfactants is not yet
completely understood. Hence, there could be
instances where unimers dissociated from
micelles (below the CMC) may prove more
effective (through cell membrane perturbation,
for example) in promoting intracellular drug
accumulation (24, 25). In other instances,
promoting the preservation of micellar
architecture in the blood (above the CMC) may
prove more conducive to inhibiting MDR.
In the case of the former, i.e. where unimers
are necessary for intracellular drug accumu-
lation, it is not immediately evident why the
CMC of a surfactant need possess an ‘optimum’
value so long as an amount of it is administered
intravenously that causes its concentration in
the blood to not exceed its CMC. This is true
assuming that, at no point in its mechanism of
action, is either micellar assembly or ‘hydro-
phobic’ association with cell membrane com-
ponents required. For example, while it may be
possible that unimers are the predominant
species that perturb the structure of the cell
membrane, it does not preclude blockage or
inhibition events downstream not requiring
surfactant micellar assembly or micellar
structures. Furthermore, an ‘optimum’ CMC
value may be critical for unimer attachment
with, or disruption of detergent resistant
membranes such as lipid rafts and caveolae (5)
in the cell membrane and the consequent
depletion of cholesterol from the cell
membrane leading to decreased P-glycoprotein
function (4).
Organelle and species specific variation in the
structure of the plasma membrane (including
differences in the fatty acid profiles constituting
the lipid bilayer) implies that the “optimum”
CMC values for maximum Pgp inhibition may
not be similar for cells derived from different
organelles or species. This may account, in part,
for the differences in CMC (for a given HLB)
that are observed in Tables 2 through 6. Future
work that seeks to understand the relationship
between the composition of the cell membrane
and the ‘optimum’ CMC for maximum efflux
pump inhibition may prove of significant value
in this regard.
CONCLUSION
There appears to exist a set of related
‘optimum’ values of HLB and CMC at which a
surfactant may be expected to maximally inhibit
the MDR efflux pump for a given cell line in in
vitro experiments. If true, such a concept
improves on existing paradigms with regard to
several points:
1. The related attributes of HLB and CMC can
be calculated either from existing in vitro
data in the literature or from experi-
mentation with related cell lines by using the
algorithm described in this report.
2. Recognizing that the attributes of CMC and
HLB can only take on a fixed set of values
(one cannot be varied independently of the
other) and that they are related to one
another (for maximum Pgp inhibition to
occur).
3. The CMC is an important property of the
surfactant and cannot be discounted even
when administered blood concentrations of
the surfactant are below the CMC.
4. Non-toxic macromolecular surfactants can
be designed by structurally changing the
attributes of existing ones to meet the
‘optimum’ CMC/HLB criterion described
above.
5. A ‘semi-rational’ method of choosing
surfactants for a specific type of cancer may
be facilitated by this concept.
More attention should be focused on the con-
comitant administration of existing FDA
approved surfactants with chemotherapeutic
agents as an approach to reverse MDR. This
approach is likely to be more cost effective and
result in a shorter time to market than, an
approach that, (say) involves identification and
synthesis of a new chemical moiety as an MDR
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inhibitor or via structural alteration of existing
chemotherapeutic drugs to enable them to
bypass the MDR mechanism. Existing excipient
surfactants need to be subjected to more
analysis (such as is attempted in this manu-
script) and empirical research that will enable
effective MDR inhibition while minimizing
cytotoxicity.
Notwithstanding all the caveats mentioned
above, it is hoped that the empirical model pre-
sented in this paper, although imperfect, will
serve as an impetus for the development of
better ‘working hypotheses’, and eventually to a
model based on first principles. Knowing the
optimal CMC and HLB, medicinal chemists
should be able to design and manufacture
surfactants, or mix and match existing ones,
that will be maximally effective as MDR rever-
sing agents, thereby solving one of the more
insidious and challenging problems of the failu-
re of chemotherapy today.
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